Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ9ZY0)

• Drug Name: SAR-104772 Drug Info
• Synonyms: TAFIa inhibitor (stroke), sanofi-aventis; SAR-104772 (oral, stroke), sanofi-aventis

Indication

Disease Entry	ICD 11	Status	REF
Cerebrovascular ischaemia	8B1Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMQ9ZY0

Molecule-Related Drug Atlas

Drug(s) Targeting Carboxypeptidase B2 (CPB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR-126119	DMKHM7O	Cerebrovascular ischaemia	8B1Z	Phase 1	[3]
UK-396082	DMFYKDX	Thrombosis	DB61-GB90	Phase 1	[4]
DS-1040	DMXCN37	Ischemic stroke	8B11.5Z	Phase 1	[5]
AZD-9684	DMHA5ME	Thrombosis	DB61-GB90	Discontinued in Phase 2	[6]
PMID14640538C3	DMR2L6X	Discovery agent	N.A.	Investigative	[7]
DL-benzylsuccinic acid	DMHI9ZJ	Discovery agent	N.A.	Investigative	[8]
PMID19954973C4	DMDYZE5	Discovery agent	N.A.	Investigative	[4]
3-mercapto-2-(piperidin-3-yl)propanoic acid	DMPJBNC	Discovery agent	N.A.	Investigative	[9]
6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid	DMMUE05	Discovery agent	N.A.	Investigative	[10]
3-mercapto-2-(piperidin-4-yl)propanoic acid	DMYQG7A	Discovery agent	N.A.	Investigative	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carboxypeptidase B2 (CPB2)	TTP18AY	CBPB2_HUMAN	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028193)
• [2] Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009.
• [3] TAFIa inhibitors in the treatment of thrombosis. Curr Opin Drug Discov Devel. 2008 Jul;11(4):480-6.
• [4] Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6.
• [5] Clinical pipeline report, company report or official report of Daiichi Sankyo.
• [6] Clinical pipeline report, company report or official report of AstraZeneca.
• [7] Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
• [8] A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
• [9] 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
• [10] Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg Med Chem Lett. 2004 May 3;14(9):2141-5.